Companies / Switzerland
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Novartis Further Diversifies With Investment In Alcon
April 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Swiss pharmaceutical giant Novartis is set to acquire an US$11bn stake in the ophthalmic group Alcon from Nestlé. Novartis has announced that it will acquire 25% of Alcon for US$143.18 per share. The acquisition appears go against the trend of its rival pharmaceutical companies, which are generally going back to basics and focusing on core